Skip to main content
Psychedex

1cP-MiPLA

1-cyclopropanoyl-N-methyl-N-isopropyllysergamide

1Provenance card

the boundary, as counts

Sources

2824 with DOI

5 strong · 20 moderate · 3 weak

Compilations

12026-05-11T07:34:43.081Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

30last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:28:49.987Z

notice · info card · emergency

Searches

182 with no results

queries and counts on the build

Claims checked

7664 supported

64 supported · 12 not

Correspondence

0received

consent field ships in Phase 4

Edges

245

derivations recorded for this entity

Complete over 28 sources, 1 compilation, and 30 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/1cp-mipla/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-07srcPharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
  5. 2026-09-07srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
  6. 2026-09-07srcReturn of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)
  7. 2026-09-07srcReturn of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD
  8. 2026-09-07srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
  9. 2026-09-07srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
  10. 2026-09-07srcReturn of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)
  11. 2026-09-07srcAnalytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
  12. 2026-09-07srcAnalytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)
  13. 2026-09-07srcAnalytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD)
  14. 2026-09-07srcThe use of prodrugs as drugs of abuse
  15. 2026-09-07srcIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
  16. 2026-09-07srcSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
  17. 2026-09-07srcRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
  18. 2026-09-07srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
  19. 2026-09-07srcIs LSD toxic?
  20. 2026-09-07srcMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
  21. 2026-09-07srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
  22. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
  23. 2026-09-07srcAcute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
  24. 2026-09-07srcGenetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
  25. 2026-09-07srcPsychedelics and the human receptorome
  26. 2026-09-07srcHallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
  27. 2026-09-07srcSerotonin Syndrome With Concomitant Antidepressant and Tramadol: A Case Report.
  28. 2026-09-07srcLysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain
  29. 2026-09-07srcLSD Overdoses: Three Case Reports
  30. 2026-09-07srcDrug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives
  31. 2026-09-07srcStereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent
  32. 2026-09-04issueIssued emergency
  33. 2026-09-04issueIssued info_card
  34. 2026-09-04issueIssued notice
  35. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  36. 2026-06-04publicationPublication — backfill
  37. 2026-05-11revisionRevision 1
  38. 2026-05-11absenceSearched ClinicalTrials.gov for "1cP-MiPLA lysergamide psychedelic" — no results
  39. 2026-05-11absenceSearched PubChem for "1cP-MiPLA" — no results
  40. 2026-05-11genGeneration — pipeline-v5 · with 7 morepipeline-v5
  41. 2026-05-11rungeneration run

The same entries, as forms: six forms.